The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
Carey
R A
RA
Smith Kline & French, King of Prussia, PA 19406.
Jacob
L
L
D001552:Benzazepines / Q000627:therapeutic use; D003846:Deoxyepinephrine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015259:Dopamine Agents / Q000378:metabolism / Q000627:therapeutic use*; D018818:Fenoldopam; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*
D001552:Benzazepines; D015259:Dopamine Agents; D011954:Receptors, Dopamine; D004280:Dobutamine; D007980:Levodopa; C016080:N-n-propyl-N-n-butyl-beta-dopamine; C023487:ibopamine; D018818:Fenoldopam; D003846:Deoxyepinephrine; D004298:Dopamine